Clinical Trial Update: Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating pembrolizumab after curative-intent treatment for oligometastatic non-small cell lung cancer has completed, with results posted in Nov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Oligometastatic Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2019-11-12